evipedia.ai
← Back

HMB for Health & Longevity

Evidence Review created on 09/20/2026 using AI4L / Opus 5

Also known as: beta-Hydroxy-beta-methylbutyrate, β-Hydroxy-β-methylbutyric acid, 3-Hydroxy-3-methylbutanoic acid, Hydroxymethylbutyrate, Calcium HMB, HMB-FA, myHMB

Motivation

HMB (beta-hydroxy-beta-methylbutyrate) is a small compound the body makes when it breaks down leucine, one of the building blocks of protein. Only a small fraction of leucine becomes HMB, and the amount circulating in the blood falls as people get older. Because muscle tissue is both a reservoir of strength and a hub of whole-body metabolism, a compound that appears to slow muscle breakdown has drawn steady attention from people trying to hold on to physical capacity across decades.

Sold as a supplement since the mid-1990s, HMB began as a livestock growth ingredient, moved into sports nutrition, and then into hospital and nursing-home nutrition products aimed at muscle wasting. Much of the research has been funded or conducted by the companies that patented and sell it, which shapes how the results read.

This review examines what the evidence shows about HMB’s effects on muscle mass, strength and physical function; where the findings agree and where they diverge; what is known about its safety; and how it is typically used, monitored and sourced.

Benefits - Risks - Protocol - Conclusion

High-level overviews of HMB from expert platforms and from the primary literature, selected for depth rather than for the count.

No HMB content exists on peterattiamd.com, hubermanlab.com or chriskresser.com; each site’s own search returned no matching page. Lifespan.io mentions HMB only inside monthly “Rejuvenation Roundup” digests, which lack the depth required here.

Grokipedia

  • β-Hydroxy β-methylbutyric acid

    Covers chemistry, production from leucine inside the body, pharmacology, the calcium and free acid forms, uses and safety in one place, with the roughly 5% conversion figure and the 60 mg daily dietary intake.

Examine

  • HMB

    Graded outcome database across thirteen conditions, plus a safety section listing gastrointestinal complaints, a theoretical interaction with certain immune-suppressing drugs, pregnancy avoidance and current anti-doping status.

ConsumerLab

  • Does HMB Help with Weight Training?

    Independent testing organisation’s assessment of HMB for weight training and for muscle wasting, with product-quality comparisons and top picks. Most of the evidence discussion sits behind the membership wall.

Systematic Reviews

The systematic reviews and meta-analyses below pool randomized controlled trials (RCTs, studies in which participants are assigned to treatment or placebo by chance) of HMB in older adults, in clinical populations and in athletes, together with one review of its effect on blood fats.

Mechanism of Action

HMB is made inside the body from leucine, an essential amino acid. Leucine is first converted to alpha-ketoisocaproate (KIC, the keto-acid form of leucine), and roughly 5% of ingested leucine is then oxidised into HMB by the enzyme KIC dioxygenase. An ordinary diet yields about 60 mg of HMB daily; a 3 g supplement delivers what roughly 60 g of leucine would produce.

Two actions are consistently described. HMB suppresses muscle protein breakdown by damping the ubiquitin-proteasome system (the cell’s main protein-recycling machinery) and the caspase enzymes that dismantle damaged fibres. It also raises muscle protein synthesis through mTOR (mechanistic target of rapamycin, the master growth switch inside cells) and its downstream target p70S6K (a signalling enzyme that turns on protein manufacture). A human tracer study found that 3 g of the calcium salt raised synthesis from 0.046 to 0.072% per hour while cutting breakdown (Wilkinson et al., 2018).

Competing explanations exist: the proposal that HMB feeds HMG-CoA (the precursor pool for cholesterol) to repair muscle cell membranes was judged insufficiently supported in a mechanistic review, which instead proposed that HMB acts by raising blood beta-hydroxybutyrate, a ketone body (Manjarrez-Montes-de-Oca et al., 2014).

Pharmacologically, HMB is not a substrate of the cytochrome P450 enzymes that clear most medicines; it enters ordinary leucine and HMG-CoA metabolism and is partly excreted unchanged in urine. It distributes to skeletal muscle and other tissues. Half-life is 2.50 hours for the free acid and 3.17 hours for the calcium salt (Fuller et al., 2011).

Historical Context & Evolution

HMB was identified as a leucine metabolite decades earlier, but its development as a supplement began at Iowa State University, where Steven Nissen’s group studied it first as a growth ingredient for livestock. The university patented the human application and licensed it to Metabolic Technologies, Inc., which has supplied and promoted it.

The first human trial came in 1996: two resistance-training studies in which 1.5 or 3 g daily reduced markers of muscle breakdown and increased weight lifted and fat-free mass (Nissen et al., 1996). That result launched HMB into sports nutrition. It was repositioned twice: into medical nutrition for wasting in cancer and immunodeficiency, usually with arginine and glutamine, and from the 2010s into geriatrics, where preserving muscle with age became the dominant question.

The sports-nutrition claim did not survive scrutiny. When trials in trained and competitive athletes were pooled, every outcome was null (Sanchez-Martinez et al., 2018), and adding HMB to exercise in older adults added little (Courel-Ibáñez et al., 2019). The aging and clinical claims held up better but shrank. Less a debunked idea than a narrowing one: the effect looks real where muscle is actively being lost and absent where it is not.

A structural asymmetry shapes what gets studied. HMB-enriched medical nutrition products are marketed and in places reimbursed by institutional payers, whereas supervised resistance training — the cheaper, better-evidenced competitor for the same outcome — is labour-intensive and rarely funded as a product, biasing research funding and guideline attention toward the supplement.

Expected Benefits

High 🟩 🟩 🟩

Preservation of Lean Body Mass With Aging and Disuse

HMB slows muscle loss rather than adding much new tissue. Two independent pooled analyses in adults over 65 found more lean mass retained on HMB than on placebo, and the effect was largest when HMB was given without an exercise programme. The signal is strongest under muscle-wasting stress: in a bed-rest trial, HMB nearly abolished the loss controls sustained. Most of this work was funded by the patent holder or by a manufacturer of HMB-containing nutrition products.

Magnitude: Standardised mean difference (SMD, an effect size that lets studies using different measures be pooled) for muscle mass 0.35, 95% confidence interval (CI, the range in which the true value most likely lies) 0.11 to 0.59, across seven trials (Wu et al., 2015); 0.37, 95% CI 0.16 to 0.58, across nine trials, rising to 0.59 for HMB given without exercise (Lin et al., 2021). Over ten days of bed rest, controls lost 2.05 kg of lean body mass against 0.17 kg on HMB (Deutz et al., 2013).

Increased Muscle Strength

Strength responds more reliably than mass. Pooling fifteen trials across many wasting conditions produced strong evidence for a strength gain and only marginal evidence for a mass gain, with small effect sizes throughout. A separate pooling restricted to people meeting formal sarcopenia criteria (clinically diagnosed age-related muscle loss) found a larger handgrip gain. Neither analysis contained a trial at low risk of bias in every category, and industry involvement in the underlying trials is extensive.

Magnitude: Strength SMD 0.31, 95% CI 0.12 to 0.50, across fifteen trials in 2137 patients (Bear et al., 2019); handgrip SMD 0.65, 95% CI 0.05 to 1.25, in five sarcopenia trials (Gu et al., 2025). A separate pooling put the handgrip gain at 1.26 kg, 95% CI 0.41 to 2.21 (Su et al., 2024).

Fewer Postoperative Complications and Shorter Hospital Stay

Given around surgery, HMB lowers the rate of postoperative complications and shortens the hospital stay, most plausibly by protecting the muscle and immune substrate that surgical stress depletes. Eleven randomized trials pooled to a consistent effect with no measurable heterogeneity (variation in results between trials), and the same pooling found gains in arm muscle circumference, appendicular muscle mass and six-minute walking distance. The trials differ in protocol and several used HMB-containing combination drinks rather than HMB alone, so the reviewers call for better-designed replication.

Magnitude: Postoperative complications relative risk 0.50, 95% CI 0.32 to 0.79, and hospital stay shorter by 0.90 days, 95% CI −1.79 to −0.01, across eleven trials in 575 surgical patients (Hu et al., 2025).

Improved Endurance Performance and Aerobic Capacity

Pooled placebo-controlled trials in healthy adults show better endurance performance and a higher maximal oxygen uptake (VO2max, the ceiling on oxygen use during hard effort) after two to twelve weeks at 3 g daily. The effect sits apart from the null strength and body-composition results in trained athletes, and the trials pooled both trained and untrained participants. The underlying trials are small and unevenly distributed in a funnel plot (a check for missing small unfavourable studies); correcting for that imbalance roughly halved both effects without abolishing either.

Magnitude: Endurance performance SMD 0.58, 95% CI 0.28 to 0.87, and VO2max SMD 0.58, 95% CI 0.21 to 0.95, across eleven trials in 279 participants; after correcting for that imbalance, 0.38, 95% CI 0.22 to 0.53, and 0.25, 95% CI 0.09 to 0.42 (Fernández-Landa et al., 2024).

Medium 🟩 🟩

Lower Mortality in Malnourished Older Adults After Hospitalisation

A multicentre trial in 652 malnourished patients over 65, discharged after heart failure, myocardial infarction (heart attack), pneumonia or chronic lung disease, found fewer deaths at 90 days on a high-protein oral supplement containing HMB, although the trial’s own primary combined endpoint of death or readmission was not met. The tested product was not HMB alone, and the trial was designed and run by its manufacturer. It has not been replicated.

Magnitude: 90-day mortality 4.8% against 9.7%, relative risk (RR, the ratio of event rates between groups) 0.49, 95% CI 0.27 to 0.90; number needed to treat (NNT, how many must be treated to prevent one event) 20.3 (Deutz et al., 2016).

Improved Everyday Physical Functionality Without Exercise Training

In the longest controlled trial to date, twelve months of HMB with vitamin D3 improved a composite of chair-rise, timed walk and grip in older adults with insufficient vitamin D who were not exercising, with no added benefit in those who were. This is a single trial run by the patent holder, and pooled analyses of walking speed alone show no effect (Gu et al., 2025), so the functional gain is best read as modest and confined to sedentary starting points.

Magnitude: Composite functional index significantly better than control at 3, 6 and 12 months in non-exercisers; knee-extension peak torque +10.9 Nm against −5.2 Nm at 3 months; lean body mass +0.44 kg against −0.33 kg at 6 months (Rathmacher et al., 2020).

Low 🟩

Faster Recovery From Exercise-Induced Muscle Damage

Pooled trials show lower blood markers of muscle damage after hard exercise, chiefly when HMB has been taken for six weeks or more. These are indirect markers rather than clinical outcomes such as soreness or restored performance, which supports the practical value of sustaining training volume without establishing it.

Magnitude: Creatine kinase (CK, an enzyme released by damaged muscle) fell by 60.71 U/L, 95% CI −78.12 to −43.29, across ten trials; lactate dehydrogenase (LDH, a second enzyme that leaks from injured tissue) fell by 15.42 U/L, 95% CI −22.2 to −8.6 (Rahimi et al., 2018).

Reduction in Body Fat ⚠️ Conflicted

Expert consensus holds that HMB with exercise produces greater fat-mass declines, but every meta-analysis testing fat mass directly found no significant change. Net reading: HMB does not reliably reduce body fat, and the favourable claim rests on selected trials rather than pooled evidence.

Magnitude: Fat mass SMD −0.08, 95% CI −0.32 to 0.16 (Wu et al., 2015); effect size 0.03, 95% CI −0.04 to 0.35, in umbrella pooling (Bideshki et al., 2025), against the contrary consensus position (Wilson et al., 2013), issued by a society whose members earn their living selling and formulating sports supplements.

Speculative 🟨

Extended Lifespan in a Model Organism

Flies fed HMB throughout adult life kept flight ability longer, retained youthful flight-muscle mitochondria and lived longer (Nagori & Vigoreaux, 2025). Basis is animal work alone; no human survival data exist.

Support for Memory and Brain Signalling

HMB strengthened memory-related brain signalling and improved working-memory performance in rodents at doses far above human use (Barranco et al., 2022). Basis is rodent work funded by a manufacturer; no human cognitive outcome exists.

Benefit-Modifying Factors

  • Baseline HMB status: Fasting plasma HMB falls with age and is lower in women at every age; within adults it correlates with arm and leg lean mass and with grip strength (Kuriyan et al., 2016). Low baseline plausibly marks the largest headroom.

  • Training status: The clearest moderator. Pooled trials in trained and competitive athletes show no effect on any outcome (Sanchez-Martinez et al., 2018), while untrained and sedentary older adults show the largest gains; adding HMB on top of an exercise programme adds little.

  • Rate of ongoing muscle loss: Benefit tracks muscle-wasting stress. Bed rest, hospitalisation, energy restriction, immobilisation and sarcopenia are the conditions in which lean mass is preserved; weight-stable, active adults show the smallest effects.

  • Vitamin D status: The longest trial enrolled only older adults with insufficient circulating 25-hydroxyvitamin D and dosed vitamin D3 alongside HMB, so the functional benefit seen there cannot be separated from correction of a deficiency.

  • Protein and leucine intake: HMB is a leucine metabolite, so its incremental value is greatest where protein intake is low. At generous protein intakes the muscle-building signal may already be saturated, one explanation for null athlete results.

  • Sex: Blood-level testing shows no sex-by-treatment interaction, yet women’s own HMB levels are lower. Several aging trials enrolled mostly or exclusively women, so male-specific effect estimates rest on thinner data.

  • Age: Benefit concentrates at the older end of the target range. Trials in adults over 65, and especially over 75 or in frailty, dominate the positive evidence; trials in young adults are largely null.

  • Pre-existing health conditions: Cancer, chronic kidney disease, cirrhosis, chronic lung disease and post-surgical recovery all feature in the trial literature as settings of amplified benefit, because each drives accelerated muscle loss that HMB can partly offset.

  • Genetic variation: No validated marker guides response. Variants in BCAT2 and BCKDHA (the first enzymes that break leucine down) and in the vitamin D receptor gene are plausible modifiers but have never been tested against HMB response.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has been reproduced as a human clinical endpoint across more than one controlled trial, and the repeated human safety datasets — blood chemistry, haematology, liver and kidney markers, blood pressure and blood fats — show no difference from placebo.

Medium 🟥 🟥

Mild Gastrointestinal Symptoms

The commonest complaints are heartburn, nausea, upset stomach and flatulence, consistent with an acidic organic acid taken on an empty stomach. A pooled analysis of three double-blind studies found no adverse indicator of health and improved mood scores, and a rheumatoid-cachexia trial (cachexia being the severe muscle and weight loss driven by chronic disease) recorded fewer gastrointestinal complaints on HMB than on the amino-acid placebo. Severity is mild and reversible on stopping.

Magnitude: Complaints are mild, dose-related and cluster at 3 g taken without food; the controlled human safety datasets report no incidence figure for HMB alone, recording instead the absence of any significant adverse indicator across nine studies (Nissen et al., 2000), three studies (Rathmacher et al., 2004) and a twelve-week rheumatoid-cachexia trial (Marcora et al., 2005).

Low 🟥

Rise in Blood Urea Nitrogen With Combination Products

Across three double-blind studies of HMB given with arginine and glutamine, blood urea nitrogen (BUN, a marker of protein load and kidney handling) rose significantly while creatinine was unchanged, most plausibly from the added nitrogen rather than from HMB. The evidence is indirect for HMB alone.

Magnitude: BUN increased significantly (p = 0.01) on the combination against placebo, with creatinine unchanged; the report gives a significance level but no effect-size figure (Rathmacher et al., 2004).

Uncertain Effects on Glucose Handling ⚠️ Conflicted

Rodent work points one way and human work the other: supplemented trained mice developed higher fasting glucose and impaired glucose clearance, and HMB worsened steroid-induced glucose intolerance in rats, while an acute human study found no harm. Net reading: no human signal of harm, but chronic human data are absent.

Magnitude: In young men, 3 g HMB with a 75 g glucose load lowered insulin area-under-the-curve with unchanged glucose; in older men neither changed (Herrod et al., 2020). Trained mice showed fasting glucose 122 against 111 mg/dL (Schadock et al., 2020), and steroid-treated rats worsened (Nunes et al., 2013).

Speculative 🟨

Consequences of Sustained mTOR Activation

HMB switches on the same growth pathway that caloric restriction and rapamycin suppress to extend lifespan in animals. Whether years of daily activation carries a cost is untested; the basis is mechanistic only.

Unknown Safety in Pregnancy and Lactation

No human pregnancy or lactation data exist. In pigs, maternal supplementation dysregulated hormones and impaired early ovarian follicle maturation in newborn offspring (Hułas-Stasiak et al., 2019); avoidance is the standard position.

Added Calcium Load From the Calcium Salt

Calcium HMB monohydrate is roughly one-seventh calcium by weight, so a 3 g daily dose adds several hundred milligrams of calcium. No trial has measured vascular or stone outcomes from this source.

Risk-Modifying Factors

  • Kidney function: No trial has enrolled people with advanced renal impairment on HMB alone. Reduced clearance of an acid metabolite, and the calcium load of the salt form, are the plausible concerns in that group.

  • Baseline biomarkers: Elevated baseline blood urea nitrogen, elevated serum calcium, or impaired fasting glucose each shift how the small changes seen with HMB should be read, making pre-treatment values necessary for attributing any later shift.

  • Sex: No sex-by-treatment interaction appeared in blood-level testing of either form, and the safety datasets included both sexes. Sex-specific adverse-event rates have not been reported separately in any trial.

  • Age: Older adults carry more concurrent medications, more renal decline and more calcium-sensitive conditions, so the calcium-salt load and the interaction profile matter more at the upper end of the target range.

  • Pre-existing health conditions: Hypercalcaemia (abnormally high blood calcium) from any cause including overactive parathyroid glands, a history of calcium-containing kidney stones, and transplant status on mTOR-inhibitor therapy change the risk calculus most.

  • Concurrent protein intake: High-protein diets combined with HMB-plus-arginine-glutamine products compound the nitrogen load, which is the setting in which the blood urea nitrogen rise was observed.

  • Genetic variation: No variant has been shown to modify HMB adverse effects. Variants in the calcium-sensing receptor gene CASR, which sets the blood calcium set-point, are a plausible but untested modifier for the calcium salt.

Key Interactions & Contraindications

  • mTOR inhibitors (sirolimus, everolimus, temsirolimus): Caution, reduced supplement effectiveness. Rapamycin blunted HMB’s rise in muscle protein synthesis in mouse muscle cells (Eley et al., 2007). Mitigation: none available; no dose change restores the effect, and HMB is no substitute for transplant therapy.

  • Corticosteroids (prednisone, dexamethasone): Monitor. Steroids drive muscle breakdown, which HMB is used to offset, but rodent work shows HMB failed to attenuate steroid-induced glucose intolerance and may have worsened it. Mitigation: fasting glucose monitoring during concurrent use.

  • Calcium-binding oral drugs (levothyroxine, tetracyclines, fluoroquinolones, oral bisphosphonates, iron salts): Caution, reduced absorption of the drug. The calcium salt supplies several hundred milligrams of calcium. Mitigation: dosing separated by at least four hours, or the free acid form.

  • Over-the-counter calcium carbonate antacids and calcium supplements: Monitor. Additive calcium intake alongside calcium HMB can exceed intended totals, with hypercalcaemia and stone risk at the extreme. Mitigation: HMB-derived calcium counted within the daily total.

  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Monitor. Both are taken around training for soreness and both burden the stomach lining; no pharmacological interaction is documented. Mitigation: HMB taken with food when the two are combined.

  • Creatine monohydrate: Additive, no adverse interaction known. Both target strength and lean mass by separate routes, and combination products are widely sold. Mitigation is not required; the benefit overlaps rather than multiplies.

  • Vitamin D3 (cholecalciferol): Additive and deliberately paired. The longest HMB trial dosed both, and vitamin D independently improves muscle strength. Mitigation: 25-hydroxyvitamin D tracking, so the calcium load and the vitamin D dose are interpreted together.

  • Leucine, whey protein and branched-chain amino acid supplements: Additive but partly redundant. These feed the same pathway upstream of HMB, which may explain null results where protein intake is already generous. Mitigation: total protein comes first, HMB after.

  • Other muscle-directed interventions: No adverse interaction; the consequence is a missed benefit, not harm. Resistance training is the dominant competitor, and pooled trials show HMB adds little on top of it (Courel-Ibáñez et al., 2019). Mitigation: training precedes supplementation. Testosterone is untested alongside HMB.

Populations who should avoid HMB:

  • Pregnant and lactating women, on the basis of absent human data and adverse offspring findings in animal feeding studies
  • People with hypercalcaemia, overactive parathyroid glands, or a history of calcium-containing kidney stones, if using the calcium salt form
  • People with advanced chronic kidney disease (stage 4 or 5, estimated glomerular filtration rate below 30 mL/min/1.73 m²), in whom HMB has not been studied
  • Children and adolescents, for whom no safety dataset exists
  • Transplant recipients on mTOR-inhibitor immunosuppression, in whom HMB’s principal mechanism is pharmacologically blocked

Risk Mitigation Strategies

  • Gradual build-up from 1 g with food to 3 g over one week: The stepped increase limits the heartburn, nausea and flatulence that cluster at a full 3 g dose taken on an empty stomach, and reveals personal tolerance early.

  • Division of the daily dose into two or three servings: Splitting 3 g into 1 g three times daily or 1.5 g twice daily reduces gastric load and matches the dosing used in the trials that reported good tolerance.

  • Free acid form where calcium intake is already high: The free acid carries no calcium, avoiding the several hundred milligrams contributed daily by the calcium salt and the associated hypercalcaemia and kidney-stone concerns.

  • Four-hour separation of the calcium salt from calcium-binding medications: Prevents the absorption loss that calcium causes with levothyroxine, tetracyclines, fluoroquinolones, oral bisphosphonates and iron salts.

  • Blood urea nitrogen and creatinine at baseline and at three months: Detects the nitrogen-load rise seen with HMB-arginine-glutamine products, particularly where protein intake exceeds 1.6 g per kilogram daily.

  • Fasting glucose and three-month average blood sugar at baseline and at six months: Addresses the unresolved glucose-handling question raised by rodent work, and catches any drift early rather than after years of use.

  • Annual serum calcium during long-term use of the calcium salt: Mitigates cumulative calcium excess in older adults who also take calcium supplements, vitamin D or calcium-containing antacids.

  • Twelve-week trial with pre-specified measures and a stop rule: Grip strength, chair-rise time and body composition measured before and after prevent indefinite spending on a supplement that does nothing in trained, weight-stable adults (Sanchez-Martinez et al., 2018).

Therapeutic Protocol

  • Standard dose: 3 g daily of HMB, the dose used in almost every positive trial and the one popularised by Steven Nissen’s group at Iowa State University and Metabolic Technologies, Inc., which developed and patented the human application.

  • Weight-scaled alternative: 38 mg per kilogram of body mass daily, from the International Society of Sports Nutrition position stand (Wilson et al., 2013), a body whose members profit from the conclusion. For most adults this is close to 3 g.

  • Split dosing: Three 1 g servings or two 1.5 g servings across the day. The bed-rest trial used 1.5 g twice daily; splitting sustains plasma levels given the short half-life and improves tolerance.

  • Form — calcium salt: Calcium HMB monohydrate, the form in most products and most trials. Peak plasma concentration 131 µmol/L at 128 minutes, half-life 3.17 hours (Fuller et al., 2011).

  • Form — free acid: Reaches peak in one-third the time, with 76% higher peak concentration and 37% faster clearance than the calcium salt in capsule form (Fuller et al., 2015). Costlier, and no outcome trial shows superiority.

  • Half-life and its consequence: 2.50 hours for the free acid against 3.17 hours for the calcium salt. Neither form holds plasma HMB elevated for a full day, which is the pharmacological argument for splitting rather than single dosing.

  • Best time of day: No circadian advantage is established. Doses are distributed with meals; where exercise is the target, one serving 30 to 60 minutes beforehand is the conventional placement.

  • Loading period: Effects on muscle damage appear only after roughly two weeks of consistent intake, and pooled recovery data reached significance only in studies running six weeks or longer.

  • Competing approach — protein first: Several groups hold that adequate total protein with sufficient leucine at each meal makes HMB redundant, consistent with null athlete trials. Neither approach has been tested head-to-head against the other.

  • Competing approach — HMB with vitamin D3: The longest trial paired HMB with vitamin D3 in older adults with insufficient vitamin D and saw functional gains only in non-exercisers (Rathmacher et al., 2020).

  • Genetic considerations: No variant guides HMB dosing. Variants in BCAT2 and BCKDHA, the first enzymes of leucine breakdown, alter leucine flux in principle, but no trial has stratified dose by genotype.

  • Sex differences: Blood-level testing of both forms found no sex-by-treatment interaction, so dosing is not adjusted by sex. Women start from lower own-body HMB, which may raise rather than lower responsiveness.

  • Age considerations: Adults over 65, and particularly over 75, are the population in which benefit is documented. No dose reduction is used for age, though renal function is established first in the oldest users.

  • Baseline biomarker considerations: Low arm and leg lean mass, low grip strength and insufficient 25-hydroxyvitamin D each mark a starting point from which the trials recorded gains; weight-stable, well-nourished starting points recorded least.

  • Pre-existing health conditions: Active muscle loss from illness, surgery, immobilisation or energy restriction is the setting in which protocols are worth running. Kidney disease, hypercalcaemia and mTOR-inhibitor therapy redirect or preclude use.

Discontinuation & Cycling

  • Intended duration: Continuous rather than short-term where the goal is preserving muscle with age. Trials run from three weeks to twelve months, and benefits track ongoing intake rather than persisting after it.

  • Withdrawal effects: None documented. No trial reports rebound muscle loss, symptom flare or any withdrawal syndrome on stopping, consistent with a metabolite the body already produces daily.

  • Tapering: Not applicable. With a half-life under four hours and no receptor adaptation described, HMB is stopped outright; plasma levels return to their own-body baseline within a day.

  • Cycling: Not indicated. No tolerance or diminishing response has been demonstrated, and the evidence points the other way, with recovery effects strengthening after six weeks of uninterrupted intake.

  • Timing around forced inactivity: The bed-rest protocol began HMB five days before immobilisation and continued through rehabilitation, which is the one start-and-stop pattern with direct trial support.

  • Stopping for absence of effect: Where twelve weeks produce no change in grip strength, chair-rise time or lean mass in an already-trained, weight-stable adult, the pooled athlete data predict continuation will not change that.

Sourcing and Quality

  • Licensed ingredient: Most reputable products use the branded calcium HMB monohydrate supplied under the myHMB licence, which carries the manufacturing and identity documentation that unbranded bulk powder often lacks.

  • Elemental content on the label: Calcium HMB monohydrate is not pure HMB. A label stating 3 g of calcium HMB delivers roughly 2.4 g of HMB plus calcium, whereas the studied 3 g target refers to HMB itself.

  • Free acid products: Sold as gels, liquid suspensions and gelatin capsules. They cost substantially more per gram, and no outcome trial has shown that the faster absorption translates into a better result.

  • Third-party testing: Certification through NSF Certified for Sport or Informed Choice confirms identity, potency and absence of banned substances, which matters because HMB is frequently sold blended with other performance ingredients.

  • Proprietary blends: Blends that bury HMB among creatine, arginine or adenosine triphosphate rarely disclose the HMB dose, making it impossible to know whether the studied 3 g is actually delivered.

  • Combination medical nutrition products: HMB-with-arginine-and-glutamine drinks and high-protein formulations are the tested products in clinical wasting, but they are not equivalent to HMB alone and carry a larger nitrogen load.

  • Form stability and taste: Calcium HMB powder is acidic and unpalatable in water; capsules remove the taste problem and reduce the gastric irritation reported with the loose powder.

Practical Considerations

  • Time to effect: Markers of muscle damage shift after roughly two weeks; strength and lean mass changes in trials emerge over eight to twelve weeks; the functional composite in the twelve-month trial separated from control at three months.

  • Pitfall — expecting hypertrophy (muscle growth) in trained lifters: Pooled trials in trained and competitive athletes found no effect on bench press, leg press, body mass, fat-free mass or fat mass at any dose or duration (Sanchez-Martinez et al., 2018).

  • Pitfall — substituting HMB for protein: HMB is a downstream leucine metabolite, not a protein source. It supplies no amino acids for building tissue and cannot compensate for inadequate daily protein intake.

  • Pitfall — underdosing or intermittent use: Doses below 1.5 g daily and stop-start intake both fall outside the protocols that produced results; the recovery benefit reached significance only in studies of six weeks or more.

  • Pitfall — expecting benefit without ongoing muscle loss: The effect concentrates where tissue is actively being lost. Weight-stable, active adults in mid-life sit in the population where trials are most often null.

  • Regulatory status: Sold as a dietary supplement under the US Dietary Supplement Health and Education Act, so it is not reviewed for efficacy before sale. It is not prohibited under the World Anti-Doping Agency list.

  • Cost and accessibility: Widely available and inexpensive as the calcium salt, roughly the price of a creatine supplement. Free acid gels and licensed medical nutrition drinks cost several times more per gram of HMB.

Interaction with Foundational Habits

  • Sleep: No direct interaction. HMB is not stimulatory and has no documented effect on sleep. The indirect route runs the other way: sleep loss accelerates muscle protein breakdown, the process HMB opposes, so poor sleep enlarges the deficit it is asked to offset.

  • Nutrition: Direct and partly redundant. Diet supplies about 60 mg of HMB daily, and supplementation adds what 60 g of leucine would produce. Glucose taken alongside delays the HMB peak (Vukovich et al., 2001), so pre-exercise doses may need two hours. Adequate protein comes first; HMB adds least where leucine intake is already generous.

  • Exercise: Potentiating in the untrained and neutral in the trained. Resistance training remains dominant, and pooled trials in adults over 50 show HMB adds little on top of it (Courel-Ibáñez et al., 2019). The clearest use is the inverse case, protecting tissue when training stops. One serving before a session is conventional.

  • Stress management: Indirect, through breakdown driven by the stress hormone cortisol. HMB opposes the muscle breakdown that stress hormones accelerate, and steroid-induced wasting is a standard model for testing it. The caution is the same coin’s other face: in rats HMB did not attenuate steroid-induced glucose intolerance, so chronic steroid therapy argues for glucose monitoring.

Monitoring Protocol & Defining Success

Before starting, a baseline set of measurements makes any later change interpretable. Body composition by dual-energy X-ray absorptiometry, grip strength by dynamometer and a timed chair-rise establish the outcomes HMB is meant to move; a metabolic panel covering kidney markers, calcium and fasting glucose establishes the safety side, and 25-hydroxyvitamin D establishes whether a correctable deficiency is present alongside. Ongoing monitoring follows a simple cadence: functional measures at 12 weeks, then every 6 months; laboratory markers at 3 months, then annually; body composition every 6 to 12 months, since lean-mass changes are small and accumulate slowly. Success is defined against the individual’s own baseline rather than against a population norm, because the documented effect sizes are small and fall within the measurement error of a single reading.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Appendicular lean mass index Above 7.0 kg/m² in men, 5.5 kg/m² in women The outcome HMB most directly targets Appendicular means the muscle of the arms and legs, measured by dual-energy X-ray absorptiometry (DXA, a low-dose scan separating lean, fat and bone). These are the sarcopenia cut-points; repeat readings belong on the same machine, fasted and hydrated
Grip strength Above 27 kg in men, 16 kg in women The strength outcome with the most consistent trial support Hand dynamometer, best of three per hand, seated with elbow at 90°. Same time of day at each visit
Chair-rise time (five repetitions) Under 12 seconds Whole-body functional capacity, the endpoint that matters for independence Part of the composite that improved in the twelve-month trial. No equipment needed; timed from seated to fifth stand
Walking speed over 4 m Above 1.0 m/s Independent predictor of later disability Pooled trials show no HMB effect on gait speed (Gu et al., 2025), so it is tracked as a safety-of-function marker rather than an expected gain
Blood urea nitrogen 10–18 mg/dL Detects the nitrogen-load rise seen with HMB-arginine-glutamine products Conventional reference range extends to 20–24 mg/dL. Fasting, paired with creatinine, and interpreted against protein intake
Creatinine and estimated glomerular filtration rate eGFR above 60 mL/min/1.73 m²; creatinine mid-range for sex Confirms kidney handling before and during chronic use eGFR is estimated glomerular filtration rate, a calculated measure of kidney clearance. Fasting, and not sampled after heavy exercise or creatine loading, both of which raise creatinine
Serum calcium, albumin-corrected 9.0–10.0 mg/dL Tracks the added calcium load from the calcium salt form Relevant only to calcium HMB, not the free acid. Paired with albumin and, if raised, with parathyroid hormone
Fasting glucose and HbA1c Glucose 75–90 mg/dL; HbA1c under 5.4% Addresses the unresolved glucose-handling question raised by rodent work HbA1c is glycated haemoglobin, a three-month average of blood sugar. Conventional cut-point for concern is 5.7%. Fasting required for glucose, none for HbA1c
Creatine kinase 50–200 U/L in the untrained Quantifies the muscle-damage marker HMB lowers in pooled trials Rises sharply for 72 hours after unaccustomed exercise; sampled after 48 hours of rest, or the reading is uninterpretable
25-hydroxyvitamin D 40–60 ng/mL Identifies the deficiency that was corrected alongside HMB in the longest trial Conventional sufficiency starts at 30 ng/mL. Season-dependent, so measured at the same time of year
Total daily protein intake No established blood target exists; track change from the individual’s own recorded baseline, aiming at 1.2–1.6 g per kilogram Establishes whether HMB is being added on top of adequacy or in place of it Recorded from diet rather than assayed. Every HMB result is interpreted against it, since null trials cluster at generous protein intakes

Qualitative markers worth tracking alongside the laboratory panel:

  • Ease of rising from a low chair or from the floor without using the hands
  • Stair-climbing capacity and whether a handrail is needed
  • Day-to-day muscle soreness after unaccustomed effort, and how long it lasts
  • Perceived training capacity: sets completed at a given load before failure
  • Carrying capacity in ordinary tasks, such as shopping or luggage
  • Energy levels and mood, both of which were formally assessed in the human safety datasets
  • Digestive comfort in the hours after each dose

Emerging Research

  • HMB with a second longevity compound in adults over 65: A 120-participant randomized trial is testing HMB and 2-hydroxybenzylamine, alone and combined, over 90 days, with muscle mass by D3-creatine dilution as the primary endpoint and cognitive function among the secondary ones (NCT07419633). The first to test HMB against a second longevity compound.

  • HMB against a herbal comparator in pre-frail older adults: A phase 2 trial of 90 pre-frail participants comparing a traditional Chinese medicine formula with HMB, with change in handgrip strength at week 12 as the primary endpoint and bone status alongside (NCT07597850).

  • HMB-enriched amino acids in cirrhosis: A 24-participant trial measuring the fractional synthesis rate of skeletal muscle against balanced amino acids (NCT05166499). Directly tests whether HMB adds anything to amino acids rather than merely to placebo.

  • Creatine plus HMB in Down syndrome: A 50-participant trial of chronic combined supplementation on lean mass, oxidative stress, inflammation, strength and body composition (NCT07213063). Relevant to whether the two agents interact.

  • HMB and inflammation in head and neck cancer: A 66-participant placebo-controlled trial measuring interleukin-6, tumour necrosis factor alpha and C-reactive protein (NCT07675421). Tests the anti-inflammatory mechanism that has so far rested on laboratory work.

  • Whether HMB adds anything to sufficient protein: The central unresolved question. A human tracer study showed the calcium salt alone raises protein synthesis (Wilkinson et al., 2018), but no trial has tested HMB against matched leucine at a generous protein intake.

  • Evidence that could weaken the case — critical illness: Nine pooled trials found no effect of HMB on mortality, ventilation duration, intensive care or hospital stay, body weight, quadriceps thickness or muscle area (Ren et al., 2025).

  • Evidence that could weaken the case — cancer: A systematic review of HMB in cancer found the trial base small, heterogeneous and frequently compromised by poor compliance (Prado et al., 2022), leaving unsettled the wasting indication that drove commercial development.

  • Evidence that could strengthen the case — lifespan beyond muscle: Lifelong HMB feeding extended survival and preserved flight-muscle mitochondria in flies (Nagori & Vigoreaux, 2025), raising a mitochondrial mechanism no human trial has yet examined.

Conclusion

HMB is a compound the body makes when it breaks down one of the building blocks of protein, sold as a supplement for holding on to muscle. The evidence is clearest where muscle is actively being lost: in older adults, in people recovering from illness or surgery, and during enforced inactivity, where repeated pooling of trials shows small but consistent gains in muscle mass and strength. The same pooling finds little or nothing for muscle size and strength in already-trained adults, though separate pooling points to better endurance and aerobic capacity, and the effects on walking speed and on body fat remain unsettled. A single large trial in malnourished older patients after hospital discharge reported fewer deaths, a result that stands alone.

Safety looks favourable. Blood chemistry, liver and kidney markers, blood pressure and blood fats have been examined repeatedly without signs of harm, and the complaints that do appear are mild and digestive. Long-term use in healthy people is unstudied; whether years of nudging a growth pathway carries a cost, and whether the supplement adds anything on top of enough protein and hard training, are unresolved.

Two features characterise the evidence base. Most of the foundational work was produced by the patent holder, by the maker of the medical nutrition products that contain it, and by a sports-nutrition society whose members earn their living in that industry. And the effect sizes are small enough that modest bias could account for them.

Top - Benefits - Risks - Protocol